Morgan Stanley
ANTX icon

Morgan Stanley’s AN2 Therapeutics ANTX Stock Holding History

Morgan Stanley’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
49,379
-184,808
-79% -$795K ﹤0.01% 5878
2026
Q1 		$801K Buy
234,187
+4,417
+2% +$9.12K ﹤0.01% 5257
2025
Q4 		$262K Buy
229,770
+39,000
+20% +$45.6K ﹤0.01% 5816
2025
Q3 		$242K Buy
190,770
+12,527
+7% +$14.3K ﹤0.01% 5814
2025
Q2 		$189K Buy
178,243
+177,943
+59,314% +$212K ﹤0.01% 5871
2025
Q1 		$408 Hold
300
– – ﹤0.01% 7401
2024
Q4 		$414 Sell
300
-3
-1% -$4 ﹤0.01% 7363
2024
Q3 		$324 Sell
303
-17,158
-98% -$29.8K ﹤0.01% 7345
2024
Q2 		$37.5K Buy
17,461
+13,297
+319% +$31.7K ﹤0.01% 6260
2024
Q1 		$13.5K Buy
4,164
+833
+25% +$9.06K ﹤0.01% 6590
2023
Q4 		$68.3K Buy
3,331
+546
+20% +$9.13K ﹤0.01% 6068
2023
Q3 		$44.8K Sell
2,785
-39,457
-93% -$447K ﹤0.01% 6211
2023
Q2 		$359K Sell
42,242
-3,290
-7% -$23.7K ﹤0.01% 5382
2023
Q1 		$449K Buy
45,532
+4,227
+10% +$47K ﹤0.01% 5320
2022
Q4 		$394K Buy
41,305
+1,072
+3% +$14.4K ﹤0.01% 5358
2022
Q3 		$699K Sell
40,233
-98
-0.2% -$1.14K ﹤0.01% 5095
2022
Q2 		$313K Buy
40,331
+39,446
+4,457% +$522K ﹤0.01% 5660
2022
Q1 		$14K Buy
+885
New +$13.4K ﹤0.01% 7278

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Morgan Stanley's ANTX Position: Q2 2026 in Review

Morgan Stanley reduced its AN2 Therapeutics (ANTX) stake by 79% in Q2 2026, selling an estimated $795K and leaving 49,379 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #5878.

Morgan Stanley first reported a position in ANTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $801K in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Morgan Stanley held 49,379 shares of AN2 Therapeutics worth $239K as of Q2 2026.
  • Morgan Stanley sold 184,808 AN2 Therapeutics shares in Q2 2026, an estimated $795K.
  • AN2 Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5878 holding.
  • Morgan Stanley first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Morgan Stanley's AN2 Therapeutics position peaked at $801K in Q1 2026.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.